Michel Marty

5.0k total citations · 1 hit paper
47 papers, 3.0k citations indexed

About

Michel Marty is a scholar working on Surgery, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Michel Marty has authored 47 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Surgery, 20 papers in Oncology and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Michel Marty's work include Nausea and vomiting management (13 papers), Cancer Treatment and Pharmacology (9 papers) and HER2/EGFR in Cancer Research (8 papers). Michel Marty is often cited by papers focused on Nausea and vomiting management (13 papers), Cancer Treatment and Pharmacology (9 papers) and HER2/EGFR in Cancer Research (8 papers). Michel Marty collaborates with scholars based in France, United States and Netherlands. Michel Marty's co-authors include L. Mauriac, Francesco Cognetti, David Robert Grimes, Stephen Chan, Antonio Antón, M. Tubiana-Hulin, Aňa Lluch, Pierfranco Conté, D Maraninchi and John Kennedy and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Michel Marty

47 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

2005 1.2k citations Michel Marty, Francesco Cognetti et al. IRIS UNIMORE (University of Modena and Reggio Emilia) profile →

Peers

Countries citing papers authored by Michel Marty

Since Specialization

Citations

This map shows the geographic impact of Michel Marty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michel Marty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michel Marty more than expected).

Fields of papers citing papers by Michel Marty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michel Marty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michel Marty. The network helps show where Michel Marty may publish in the future.

Co-authorship network of co-authors of Michel Marty

This figure shows the co-authorship network connecting the top 25 collaborators of Michel Marty. A scholar is included among the top collaborators of Michel Marty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michel Marty. Michel Marty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies 2015 ·Leukemia & lymphoma ·Stéphane Leprêtre, (unknown), Pierre Feugier, Michel Marty, Gilles Salles	4
2	Distinct tumor protein p53 mutants in breast cancer subgroups 2012 ·International Journal of Cancer ·Anne Dumay, Jean‐Paul Feugeas, (unknown), Jacqueline Lehmann‐Che, Philippe Bertheau, Marc Espié, Louis‐François Plassa, Paul Cottu, Michel Marty, Fabrice André, Christos Sotiriou, Lajos Pusztai, Hugues de Thé	95
3	Anticorps monoclonaux thérapeutiques en cancérologie 2012 ·Pathologie Biologie ·(unknown), (unknown), Michel Marty	1
4	Combining molecular targeted therapies 2011 ·Anti-Cancer Drugs ·Xavier Pivot, (unknown), Antoine Thiery-Vuillemin, Marc Espié, Michel Marty	7
5	Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers 2010 ·The Oncologist ·Jacqueline Lehmann‐Che, Fabrice André, Christine Desmedt, Chafika Mazouni, Sylvie Giacchetti, Elisabeth Turpin, Marc Espié, Louis‐François Plassa, Michel Marty, Philippe Bertheau, Christos Sotiriou, Martine Piccart, W. Fraser Symmans, Lajos Pusztai, Hugues de Thé	41
6	Lessons from French national guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients 2010 ·Thrombosis Research ·Dominique Farge, C. Durant, Stéphane Villiers, Anne Long, Alfred Mahr, Michel Marty, P. Debourdeau	35
7	Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer? 2008 ·Supportive Care in Cancer ·P. Debourdeau, Ismaı̈l Elalamy, (unknown), P. Méria, Jean Marc Gornet, (unknown), (unknown), Michel Marty, Dominique Farge	20
8	The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumab 2008 ·European Journal of Cancer ·Michel Marty, Xavier Pivot	49
9	Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. breakdown → 2005 ·IRIS UNIMORE (University of Modena and Reggio Emilia) ·Michel Marty, Francesco Cognetti, D Maraninchi, (unknown), L. Mauriac, M. Tubiana-Hulin, Stephen Chan, David Robert Grimes, Antonio Antón, Aňa Lluch, John Kennedy, Kenneth J. O’Byrne, (unknown), (unknown), (unknown), (unknown), Pierfranco Conté	1162
10	The advisory process for anticancer drug regulation: a global perspective 2005 ·Annals of Oncology ·Ann T. Farrell, (unknown), Akiko Hori, (unknown), (unknown), (unknown), Michel Marty, Ramzi Dagher, Richard Pazdur	16
11	In Vivo Retroviral Mediated Gene Transfer into Bladder Urothelium Results in Preferential Transduction of Tumoral Cells 2004 ·European Urology ·(unknown), P. Mongiat-Artus, Patrick Devauchelle, A. Lesourd, (unknown), A. Le Duc, Michel Marty, Olivier Cussenot, Odile Cohen‐Haguenauer	3
12	Use of abdominal aortic endovascular prostheses in France from 1999 to 2001 2003 ·Journal of Vascular Surgery ·Jean‐Baptiste Ricco, Olivier Goëau-Brissonnière, Marie-Hélène Rodde-Dunet, Michel Marty, P Fender, (unknown), (unknown)	15
13	Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy 2002 ·The Lancet ·P Bertheau, François Plassa, Marc Espié, E Turpin, Anne de Roquancourt, Michel Marty, F. Lerebours, Yves Beuzard, Anne Janin, Hugues de Thé	126
14	Expression of amphiregulin and epidermal growth factor receptor in human breast cancer: analysis of autocriny and stromal-epithelial interactions 2001 ·The Journal of Pathology ·Lin Ma, Anne de Roquancourt, Philippe Bertheau, Sylvie Chevret, G. Millot, Xavier Sastre‐Garau, Marc Espié, Michel Marty, Anne Janin, Fabien Calvo	32
15	Delayed emesis following anticancer chemotherapy 1998 ·Supportive Care in Cancer ·Mark G. Kris, Fausto Roila, P.H.M. de Mulder, Michel Marty	23
16	Consensus regarding multiple day and rescue antiemetic therapy 1998 ·Supportive Care in Cancer ·P.H.M. de Mulder, Fausto Roila, Mark G. Kris, Michel Marty	11
17	Phase II study of a new vinca alkaloid derivative, S12363, in advanced breast cancer 1995 ·Cancer Chemotherapy and Pharmacology ·Antoine Adenis, (unknown), P. Fumoleau, P Pouillart, Michel Marty, B. Giroux, J. Bonneterre	4
18	Combined chemotherapy-radiotherapy in advanced Hodgkin's disease: Results of a prospective clinical trial with 70 stage IIIB-IV patients 1993 ·International Journal of Radiation OncologyBiologyPhysics ·Christophe Fermé, Éric Lepage, Pauline Brice, M F D'Agay, Jean-Paul Fermand, Sylvie Castaigné, J Frija, (unknown), Michel Marty, Christian Gisselbrecht	8
19	A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic-induced emesis 1992 ·European Journal of Cancer ·Michel Marty	24
20	Comparison of the 5-Hydroxytryptamine₃(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced Emesis 1990 ·New England Journal of Medicine ·Michel Marty, P Pouillart, Suzy Scholl, Jean Pierre Droz, Mohamed Azab, (unknown), Éric Pujade-Lauraine, Bernard Paule, (unknown), J Bons	328

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact